Virtus Biotech Clinical Trials ETF
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
A fund that holds many companies, so profit, growth, price and debt are not measured for it as for one company.
AI analysis
An AI analyst reads Virtus Biotech Clinical Trials ETF's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
Not enough data
Questions about Virtus Biotech Clinical Trials ETF
Is Virtus Biotech Clinical Trials ETF a good stock to buy?
A fund that holds many companies, so profit, growth, price and debt are not measured for it as for one company. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Virtus Biotech Clinical Trials ETF AI analysis
What does Virtus Biotech Clinical Trials ETF do?
The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index, which tracks the performance of select clinical trials stage biotechnology companies.Effective February 27, this Fun… It is in Asset Management.
How has Virtus Biotech Clinical Trials ETF stock done over the past year?
Up 33.8% over the past twelve months, to $43.14. It traded between $31.46 and $56.03 and is 23.0% below its high.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.